CRYOPORT INC (CYRX) Stock Fundamental Analysis

NASDAQ:CYRX • US2290503075

8.35 USD
+0.11 (+1.33%)
At close: Feb 13, 2026
8.35 USD
0 (0%)
After Hours: 2/13/2026, 4:54:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall CYRX gets a fundamental rating of 4 out of 10. We evaluated CYRX against 58 industry peers in the Life Sciences Tools & Services industry. The financial health of CYRX is average, but there are quite some concerns on its profitability. CYRX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year CYRX was profitable.
  • In the past year CYRX has reported a negative cash flow from operations.
  • CYRX had negative earnings in each of the past 5 years.
  • In the past 5 years CYRX reported 4 times negative operating cash flow.
CYRX Yearly Net Income VS EBIT VS OCF VS FCFCYRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

  • The Return On Assets of CYRX (7.69%) is better than 86.21% of its industry peers.
  • The Return On Equity of CYRX (11.61%) is better than 84.48% of its industry peers.
Industry RankSector Rank
ROA 7.69%
ROE 11.61%
ROIC N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
CYRX Yearly ROA, ROE, ROICCYRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • Looking at the Profit Margin, with a value of 31.31%, CYRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • The Gross Margin of CYRX (46.58%) is comparable to the rest of the industry.
  • CYRX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 31.31%
GM 46.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
CYRX Yearly Profit, Operating, Gross MarginsCYRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • CYRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CYRX has been increased compared to 1 year ago.
  • The number of shares outstanding for CYRX has been increased compared to 5 years ago.
  • Compared to 1 year ago, CYRX has an improved debt to assets ratio.
CYRX Yearly Shares OutstandingCYRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CYRX Yearly Total Debt VS Total AssetsCYRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • CYRX has an Altman-Z score of 0.50. This is a bad value and indicates that CYRX is not financially healthy and even has some risk of bankruptcy.
  • CYRX has a Altman-Z score of 0.50. This is in the lower half of the industry: CYRX underperforms 60.34% of its industry peers.
  • A Debt/Equity ratio of 0.36 indicates that CYRX is not too dependend on debt financing.
  • CYRX has a Debt to Equity ratio (0.36) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z 0.5
ROIC/WACCN/A
WACC8.89%
CYRX Yearly LT Debt VS Equity VS FCFCYRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 15.77 indicates that CYRX has no problem at all paying its short term obligations.
  • CYRX's Current ratio of 15.77 is amongst the best of the industry. CYRX outperforms 98.28% of its industry peers.
  • CYRX has a Quick Ratio of 15.01. This indicates that CYRX is financially healthy and has no problem in meeting its short term obligations.
  • CYRX has a Quick ratio of 15.01. This is amongst the best in the industry. CYRX outperforms 98.28% of its industry peers.
Industry RankSector Rank
Current Ratio 15.77
Quick Ratio 15.01
CYRX Yearly Current Assets VS Current LiabilitesCYRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • CYRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 157.07%, which is quite impressive.
  • The Revenue for CYRX has decreased by -15.86% in the past year. This is quite bad
  • Measured over the past years, CYRX shows a very strong growth in Revenue. The Revenue has been growing by 46.45% on average per year.
EPS 1Y (TTM)157.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
Revenue 1Y (TTM)-15.86%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-21.94%

3.2 Future

  • CYRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.53% yearly.
  • Based on estimates for the next years, CYRX will show a small growth in Revenue. The Revenue will grow by 1.03% on average per year.
EPS Next Y222.58%
EPS Next 2Y19.03%
EPS Next 3Y13.99%
EPS Next 5Y13.53%
Revenue Next Year-23.65%
Revenue Next 2Y-8.72%
Revenue Next 3Y-3%
Revenue Next 5Y1.03%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CYRX Yearly Revenue VS EstimatesCYRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
CYRX Yearly EPS VS EstimatesCYRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 7.14 indicates a rather cheap valuation of CYRX.
  • Based on the Price/Earnings ratio, CYRX is valued cheaper than 98.28% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.97. CYRX is valued rather cheaply when compared to this.
  • The Forward Price/Earnings Ratio is negative for CYRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 7.14
Fwd PE N/A
CYRX Price Earnings VS Forward Price EarningsCYRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYRX Per share dataCYRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as CYRX's earnings are expected to grow with 13.99% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y19.03%
EPS Next 3Y13.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CYRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRYOPORT INC

NASDAQ:CYRX (2/13/2026, 4:54:23 PM)

After market: 8.35 0 (0%)

8.35

+0.11 (+1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04
Earnings (Next)03-02
Inst Owners103.06%
Inst Owner Change0.06%
Ins Owners3.99%
Ins Owner Change2.97%
Market Cap418.08M
Revenue(TTM)190.26M
Net Income(TTM)59.58M
Analysts85.33
Price Target13.49 (61.56%)
Short Float %6.17%
Short Ratio6.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)486.84%
Min EPS beat(2)16.41%
Max EPS beat(2)957.28%
EPS beat(4)3
Avg EPS beat(4)236.36%
Min EPS beat(4)-40.53%
Max EPS beat(4)957.28%
EPS beat(8)5
Avg EPS beat(8)88.31%
EPS beat(12)7
Avg EPS beat(12)52.28%
EPS beat(16)8
Avg EPS beat(16)33.95%
Revenue beat(2)2
Avg Revenue beat(2)5.82%
Min Revenue beat(2)4.86%
Max Revenue beat(2)6.79%
Revenue beat(4)2
Avg Revenue beat(4)1.51%
Min Revenue beat(4)-5.29%
Max Revenue beat(4)6.79%
Revenue beat(8)2
Avg Revenue beat(8)-1.64%
Revenue beat(12)3
Avg Revenue beat(12)-1.56%
Revenue beat(16)3
Avg Revenue beat(16)-2.77%
PT rev (1m)0%
PT rev (3m)4.39%
EPS NQ rev (1m)2.11%
EPS NQ rev (3m)-4.46%
EPS NY rev (1m)1.68%
EPS NY rev (3m)686.82%
Revenue NQ rev (1m)-0.4%
Revenue NQ rev (3m)-1.54%
Revenue NY rev (1m)0.45%
Revenue NY rev (3m)1.52%
Valuation
Industry RankSector Rank
PE 7.14
Fwd PE N/A
P/S 2.2
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)1.17
EY14.01%
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS3.8
BVpS10.25
TBVpS6.98
PEG (NY)0.03
PEG (5Y)N/A
Graham Number16.43
Profitability
Industry RankSector Rank
ROA 7.69%
ROE 11.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 31.31%
GM 46.58%
FCFM N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
F-Score6
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 69.06%
Cap/Sales 10.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.77
Quick Ratio 15.01
Altman-Z 0.5
F-Score6
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)112.93%
Cap/Depr(5y)112.05%
Cap/Sales(3y)12.92%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)157.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
EPS Next Y222.58%
EPS Next 2Y19.03%
EPS Next 3Y13.99%
EPS Next 5Y13.53%
Revenue 1Y (TTM)-15.86%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-21.94%
Revenue Next Year-23.65%
Revenue Next 2Y-8.72%
Revenue Next 3Y-3%
Revenue Next 5Y1.03%
EBIT growth 1Y44.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year96.15%
EBIT Next 3Y29.15%
EBIT Next 5Y19.06%
FCF growth 1Y13.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3666.43%
OCF growth 3YN/A
OCF growth 5YN/A

CRYOPORT INC / CYRX FAQ

What is the ChartMill fundamental rating of CRYOPORT INC (CYRX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CYRX.


Can you provide the valuation status for CRYOPORT INC?

ChartMill assigns a valuation rating of 4 / 10 to CRYOPORT INC (CYRX). This can be considered as Fairly Valued.


What is the profitability of CYRX stock?

CRYOPORT INC (CYRX) has a profitability rating of 3 / 10.


What are the PE and PB ratios of CRYOPORT INC (CYRX) stock?

The Price/Earnings (PE) ratio for CRYOPORT INC (CYRX) is 7.14 and the Price/Book (PB) ratio is 0.81.


How financially healthy is CRYOPORT INC?

The financial health rating of CRYOPORT INC (CYRX) is 4 / 10.